Design, synthesis, and biological evaluation of novel (E)-1-arylethan-1-one O-((3-arylisoxazol-5-yl) methyl) oxime derivatives as potent non-nucleoside HBV inhibitors
作者:Yunhou Huang、Na Liu、Qiuyue Ning、Min Zhou、Ning Zang、Taoyuan Liang、Wanxing Wei
DOI:10.1016/j.molstruc.2022.132789
日期:2022.7
A series of novel O-((3-arylisoxazol-5-yl) methyl) oxime derivatives were synthesized by highly regioselective dipolar cycloadditions of nitrile oxides with (E)-1-arylethan-1-one O-prop-2-yn-1-yl oxime substrates. Results showed that in the formation of (E)-N-hydroxy-3,4-dimethoxybenzimidoyl chloride, chlorinating substitution in phenyl occurred when excess N-chlorosuccinimide. The crystal structure
通过腈氧化物与 ( E )-1-arylethan-1-one O-prop-2-yn-的高区域选择性偶极环加成反应合成了一系列新型 O-((3-arylisoxazol-5-yl)methyl) 肟衍生物。1-基肟底物。结果表明,在(E)-N-hydroxy-3,4-dimethoxybenzimidoyl chloride 的形成过程中,过量的 N-氯代丁二酰亚胺发生了苯基的氯化取代。该系列化合物中10个的晶体结构为顺式环化产物,-C(CH 3 )=NO-部分为E构型。作为三斜晶体,异恶唑-5-基环(B)和苯环(A) 为 57.43°,二面角为 25.22°。对这些化合物的抗HBV活性进行了筛选。结果显示化合物11、19和12有效抑制 HBeAg(IC 50 = 158.28 ± 0.02、127.51 ± 0.01 和 213.26 ± 0.04 分别)。化合物11、19和23对 HBsAg